Objectives: This study aims to systematically review the literature to determine whether a staged or simultaneous approach to native nephrectomy in ADPKD is the optimal approach in terms of morbidity and graft outcomes.
Merck Inc announced that the European Commission has approved Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC) at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
This guideline, relating to the provision of a percutaneously placed enteral tube feeding service, is focused upon a specific area of nutrition provision that has not been previously targeted.
Merck Inc. known as MSD outside of the United States and Canada, announced that the Phase III KEYNOTE-564 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, met its key secondary endpoint of overall survival (OS), for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
Merck Inc., known as MSD outside of the United States and Canada, announced results from the Phase III KEYNOTE-564 trial evaluating Keytruda Merck’s anti-PD-1 therapy, for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
This guideline is restricted to GI endoscopy but we cover elective and acute or emergency procedures.
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care.
-Pfizer Inc. has announced that the independent Data Monitoring Committee for the Phase III ATLAS trial evaluating Inlyta (axitinib) as...
This guideline covers identifying and caring for adults who are malnourished or at risk of malnutrition in hospital or in their own home or a care home.
To update and expand the 2013 Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the ICU.